Journals / Kocaeli Tıp Dergisi / 2022 / Cilt: 11 - Sayı: 1

The Importance of C-Reactive Protein for Preoperative Evaluation, Inoperability and Survival in Patients with Peritoneal Metastasis

Periton Metastazı olan Hastalarda Preoperatif Değerlendirme, İnoperabilite veSağkalım İçin C-Reaktif Proteinin Önemi

Pages
107–118
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This difference was found to be statistically significant (p = 0.03) In the subsequent subgroup analysis, in patient group with PCI ≥9, the CRP value was found to be significantly higher than the PCI

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: C-reactive protein (CRP) is an inflammatory marker that has predictive value for survival in many types of cancer.
📊
Key Findings & Data:Method: A total of 126 patients who underwent laparotomy for cytoreductive surgery and HIPEC between 2014- 2019 were included in this study.
💡
Conclusion & Impact:This difference was found to be statistically significant (p = 0.03) In the subsequent subgroup analysis, in patient group with PCI ≥9, the CRP value was found to be significantly higher than the PCI
🔬Design:Research Article
📍Scope:2014- 2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: C-reactive protein (CRP) is an inflammatory marker that has predictive value for survival in many types of cancer. The aim of this study is to examine the preoperative CRP level as a predictive biomarker for surgery due to peritoneal carcinomatosis whether the disease is resectable or not. Method: A total of 126 patients who underwent laparotomy for cytoreductive surgery and HIPEC between 2014- 2019 were included in this study. Results: In the comparative analysis, for operated and unresectable patients, CRP values measured in the same week preoperatively were found to be statistically significant markers for operability. The CRP values were found 4.3 and 18 g/L, respectively. This difference was found to be statistically significant (p = 0.03) In the subsequent subgroup analysis, in patient group with PCI ≥9, the CRP value was found to be significantly higher than the PCI

Özet

Giriş: C-reaktif protein (CRP), birçok kanser türünde sağkalım için prediktif değere sahip inflamatuar bir belirteçtir. Bu çalışmanın amacı, hastalığın rezektabl olup olmadığına peritoneal karsinomatozise bağlı cerrahide prediktif biyo-belirteç olarak preoperatif CRP düzeyini incelemektir. Yöntem: 2014- 2019 yılları arasında sitoredüktif cerrahi ve HİPEK için laparotomi yapılan 126 hasta çalışmaya dahil edildi. Bulgular: Karşılaştırmalı analizde ameliyatlı ve rezeke edilemeyen hastalarda ameliyat öncesi aynı hafta ölçülen CRP değerlerinin ameliyat için istatistiksel olarak anlamlı belirteçler olduğu görüldü. CRP değerleri sırasıyla 4.3 ve 18 g / L bulundu. Bu fark istatistiksel olarak anlamlı bulundu (p = 0.03). Sonraki alt grup analizinde PCI ≥9 olan hasta grubunda CRP değeri PCI

🔖

Cite This Article

ÖZGÜN, Y. M., PİŞKİN, E., AYDIN, O., ÇOLAKOĞLU, M. K., BOSTANCI, E. B., ÖTER, V. (2022). The Importance of C-Reactive Protein for Preoperative Evaluation, Inoperability and Survival in Patients with Peritoneal Metastasis. Kocaeli Tıp Dergisi, Cilt: 11 - Sayı: 1, 107–118. https://ajindex.com/articles/574640

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Nassour I, Polanco PM. Current Management of Peritoneal Carcinomatosis From Colorectal Cancer: The Role of Cytoreductive Surgery and Hyperthermic Peritoneal Chemoperfusion. Curr Colorectal Cancer Rep. 2017;13(2):144- 153. Epub 2017 Apr 8. PMID: 28890671; PMCID: PMC5586145.
  2. Lemoine L, Sugarbaker P, Van der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol. 2016 14;22(34):7692-707. PMID: 27678351; PMCID: PMC5016368.
  3. Valle M, Federici O, Garofalo A. Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment. Surg Oncol Clin N Am. 2012;21(4):515-31. PMID: 23021713.
  4. Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107(6):566-73. Epub 2012 Jun 11. PMID: 22688776.
  5. Verwaal VJ,Bruin S,Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426-32. Epub 2008 Jun 3. PMID: 18521686.
  6. Sugarbaker PH, Editor. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas. Woodbury: CineMed Publishing; 2012
  7. Deraco M, Kusamura S, Corbellini C, Guaglio M, Paviglianiti C, Baratti D. Treatment principles for peritoneal surface malignancies. Minerva Chir. 2016;71(2):124-45. Epub 2016 Feb 5. PMID: 26847729
  8. Sugarbaker PH. Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach? Gastroenterol Res Pract. 2012;2012:309417. Epub 2012 Jul 19. PMID: 22888335; PMCID: PMC3408708.
  9. Baratti D, Kusamura S, Guaglio M, Deraco M. Peritoneal metastases: challenges for the surgeon. Minerva Chir. 2015;70(3):195-215. Epub 2015 Mar 10. PMID: 25752673
  10. Dohan A, Hobeika C, Najah H, Pocard M, Rousset P, Eveno C. Preoperative assessment of peritoneal carcinomatosis of colorectal origin. J Visc Surg. 2018;